Gold Nanobipyramid‐Mediated Apoptotic Camouflage of Adipocytes for Obesity Immunotherapy
Source abstract
Abstract
Abstract Obesity treatment is a global public health challenge due to inadequate weight loss and weight regain even after endeavors with multimodal treatments. Considering the abundance of resident macrophages in adipose tissues, precise regulation of the interactions between macrophages and adipocytes may provide chances for immunotherapy of obesity. Herein, inspired by the phagocytosis of macrophages to clear apoptotic cells in homeostasis, an immunotherapy strategy for obesity treatment is proposed for the first time through apoptotic camouflage of adipocytes by PAAu BPs to activate macrophages for clearance, where PAAu BPs are gold nanobipyramids engineered with adipose‐targeting and apoptotic cell‐mimicking functions. During clearance, the macrophage is switched from pro‐inflammatory M1 to anti‐inflammatory M2, remarkably modulating the immune microenvironment of adipose tissues to prevent weight regain. After inguinal injection with PAAu BPs, the body weights of obese mice are effectively decreased by 24.4% and can be decreased by 33.3% when combined with photothermal lipolysis, and little weight regain is associated with these treatments. This study demonstrates that the strategy of camouflaging adipocytes with apoptotic features holds great potential for obesity immunotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Phagocytosis and Immune Regulation · Immune cells in cancer · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laboratory of Chemical Biology Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun Jilin 130022 China
Key Laboratory of Bionic Engineering, Ministry of Education Jilin University Changchun 130022 China
Department of Urology The First Hospital of Jilin University Changchun Jilin 130022 China
University of Science and Technology of China Hefei Anhui 230026 China
Funding
National Basic Research Program of China · China Postdoctoral Science Foundation · National Natural Science Foundation of China
References (56)
Show source-provided references
1. 10.1038/ijo.2008.24710.1038/ijo.2008.247 ↗
2. 10.1016/j.ecl.2016.04.01610.1016/j.ecl.2016.04.016 ↗
3. 10.1038/oby.2002.20210.1038/oby.2002.202 ↗
4. 10.1126/science.110434210.1126/science.1104342 ↗
5. 10.1111/j.1753-4887.2007.tb00329.x10.1111/j.1753-4887.2007.tb00329.x ↗
6. 10.1016/j.cjca.2012.01.00110.1016/j.cjca.2012.01.001 ↗
7. 10.1146/annurev-med-051613-01232810.1146/annurev-med-051613-012328 ↗
8. 10.1177/088453361141833510.1177/0884533611418335 ↗
9. 10.1016/S1359-6446(04)03244-110.1016/S1359-6446(04)03244-1 ↗
10. 10.6118/jmm.2014.20.3.9010.6118/jmm.2014.20.3.90 ↗
11. 10.1038/oby.2004.15110.1038/oby.2004.151 ↗
12. 10.1016/j.ymthe.2017.05.02010.1016/j.ymthe.2017.05.020 ↗
13. 10.1021/acsnano.7b0434810.1021/acsnano.7b04348 ↗
14. 10.1073/pnas.160384011310.1073/pnas.1603840113 ↗
15. 10.1016/j.tips.2011.01.00410.1016/j.tips.2011.01.004 ↗
16. Thyagarajan B. · Horm. Mol. Biol. Clin. Investig. · 2017 · 31 · 0016
17. 10.1038/nm104810.1038/nm1048 ↗
18. 10.2147/IJN.S17342410.2147/IJN.S173424 ↗
19. 10.1038/mt.2015.15510.1038/mt.2015.155 ↗
20. 10.1021/acsbiomaterials.7b0054910.1021/acsbiomaterials.7b00549 ↗
21. 10.1038/s41574-018-0148-410.1038/s41574-018-0148-4 ↗
22. 10.1126/science.aar406010.1126/science.aar4060 ↗
23. 10.3390/ijms2004084010.3390/ijms20040840 ↗
24. 10.1038/nm.200110.1038/nm.2001 ↗
25. S.Takeda inTher. Vaccines as Nov. Immunother. Springer Singapore2019 pp.9–20 Ch 4.10.1007/978-981-32-9628-2_2 ↗
26. 10.1038/nm.262710.1038/nm.2627 ↗
27. 10.3389/fimmu.2019.0158710.3389/fimmu.2019.01587 ↗
28. 10.1038/s41586-021-04127-510.1038/s41586-021-04127-5 ↗
29. 10.1177/204201882093090210.1177/2042018820930902 ↗
30. 10.1038/nri304110.1038/nri3041 ↗
31. 10.1007/978-3-319-48382-5_1410.1007/978-3-319-48382-5_14 ↗
32. 10.1038/cddis.2014.57910.1038/cddis.2014.579 ↗
33. 10.1194/jlr.M06408910.1194/jlr.M064089 ↗
34. 10.1172/JCI111210.1172/JCI1112 ↗
35. 10.1016/j.immuni.2007.11.01410.1016/j.immuni.2007.11.014 ↗
36. 10.1186/s12950-020-00267-z10.1186/s12950-020-00267-z ↗
37. 10.1038/nri360710.1038/nri3607 ↗
38. 10.1038/cdd.2016.1110.1038/cdd.2016.11 ↗
39. 10.1016/j.tcb.2015.08.00310.1016/j.tcb.2015.08.003 ↗
40. 10.1038/srep4646210.1038/srep46462 ↗
41. 10.1021/acs.accounts.9b0023010.1021/acs.accounts.9b00230 ↗
42. 10.1021/jacs.6b1214310.1021/jacs.6b12143 ↗
43. 10.1007/s13404-012-0067-410.1007/s13404-012-0067-4 ↗
44. 10.1016/j.omto.2017.05.00310.1016/j.omto.2017.05.003 ↗
45. 10.1038/ncomms347210.1038/ncomms3472 ↗
46. 10.1016/j.jconrel.2021.03.02210.1016/j.jconrel.2021.03.022 ↗
47. 10.1038/cdd.2014.14810.1038/cdd.2014.148 ↗
48. 10.1007/s00281-016-0555-310.1007/s00281-016-0555-3 ↗
49. 10.1016/j.physbeh.2008.01.00210.1016/j.physbeh.2008.01.002 ↗
50. 10.1038/s41366-020-0606-710.1038/s41366-020-0606-7 ↗
51. 10.1002/lsm.2323110.1002/lsm.23231 ↗
52. 10.1016/j.biocel.2017.10.01310.1016/j.biocel.2017.10.013 ↗
53. 10.1016/j.colsurfa.2019.03.06310.1016/j.colsurfa.2019.03.063 ↗
54. 10.1021/acsanm.2c0295610.1021/acsanm.2c02956 ↗
55. 10.1002/adfm.20201113010.1002/adfm.202011130 ↗
56. 10.1021/acsnano.1c0641010.1021/acsnano.1c06410 ↗